Magnisense and Indicia Announce Joint Testing Platform for Magnetic Marker-Based In Vitro Diagnostics

Magnisense, a developer of next generation immunoassays for human and animal diagnostics, food safety and environmental protection, has announced the availability of a platform for customers in the diagnostics industry to test solutions based on Magnisense's MIAtek™ technology.

The platform has been developed within a partnership with Indicia Biotechnology, an immune technology specialist based in Lyon, France.

MIAtek™ employs magnetic beads as markers, replacing the traditional enzymatic or fluorescent methods. Magnisense has already developed a portable reader which can identify and quantify a biological target using superparamagnetic beads as markers.

By linking up with Indicia, Magnisense opens the way for diagnostics or life science companies who wish to use MIAtek™ for their own applications to develop tests which are specifically adapted to the desired markers and based on their own parameters.

"Before or after acquiring a license from Magnisense, any of our customers can now rapidly judge the value of our technology thanks to our jointly-developed tests," said Luc Lenglet, CEO of Magnisense. "Indicia brings two indispensable skills to the development of MIAtek™ technology: immunoassays and reagents for the magnetic beads."

"As well as extending our range of products and services, this partnership with Magnisense allows us to work on what we see as the future generation of immunoassays based on magnetic technology," said Stéphane Legastelois, chairman of Indicia Biotechnology.

"Companies interested in Magnisense's technology can now see quickly and easily for themselves the advantages such as the increased sensitivity and the quantification of fast testing," said Legastelois.